8 completed. 3 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow XC221: new trials by email Literature Review of XC221 trials Research Report on XC221
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections XC221, Placebo - Influenza, Respiratory Viral Infection | Phase 3 | Completed | Valenta Pharm JSC | 260 | 2022-08-05 | 2023-10-10 |
| Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets XC221 100 mg tablets - Healthy | Phase 1 | Completed | Valenta Pharm JSC | 24 | 2022-02-10 | 2023-07-27 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections XC221 100 mg, XC221 200 mg, Placebo - Influenza, Viral Respiratory Infection | Phase 2 | Completed | Valenta Pharm JSC | 255 | 2021-10-01 | 2023-07-27 |
| A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 XC221, Placebo - Sars-CoV-2 Infection | Phase 3 | Completed | RSV Therapeutics LLC | 274 | 2021-06-26 | 2023-07-27 |
| A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 XC221, Placebo - SARS-CoV-2 Infection | Phase 3 | Completed | RSV Therapeutics LLC | 118 | 2020-07-25 | 2023-07-27 |
| Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI XC221, Placebo - Influenza, Acute Respiratory Viral Infections | Phase 2 | Completed | PHARMENTERPRISES LLC | 120 | 2019-01-31 | 2020-11-16 |
| Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections XC221 100 mg, XC221 200 mg, Placebo - Acute Respiratory Viral Infections, Influenza | Phase 2 | Completed | PHARMENTERPRISES LLC | 120 | 2018-02-12 | 2019-11-04 |
| Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers XC221 60 mg, XC221 200 mg, Placebo - Influenza, Acute Respiratory Infection | Phase 1 | Completed | PHARMENTERPRISES LLC | 32 | 2017-05-22 | 2018-03-08 |
Influenza, Human (5) · COVID-19 (2) · Coronavirus Infections (2)
PHARMENTERPRISES LLC (3) · Valenta Pharm JSC (3) · RSV Therapeutics LLC (2)
Russia (8)